Citadel Advisors
DERM icon

Citadel Advisors’s Journey Medical DERM Stock Holding History

Citadel Advisors’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,415
Closed -$535K – 13196
2025
Q4 		$535K Buy
69,415
+55,025
+382% +$431K ﹤0.01% 8866
2025
Q3 		$102K Buy
+14,390
New +$104K ﹤0.01% 11840
2025
Q2 		– Sell
-49,259
Closed -$291K – 12990
2025
Q1 		$291K Buy
49,259
+4,691
+11% +$23.1K ﹤0.01% 9672
2024
Q4 		$174K Buy
+44,568
New +$244K ﹤0.01% 10665
2024
Q1 		– Sell
-11,357
Closed -$65.4K – 14691
2023
Q4 		$65.4K Buy
+11,357
New +$50.6K ﹤0.01% 11474
2022
Q1 		– Sell
-10,761
Closed -$58K – 13748
2021
Q4 		$58K Buy
+10,761
New +$77.9K ﹤0.01% 13165

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's DERM Position: Q1 2026 in Review

Citadel Advisors sold out of Journey Medical (DERM) in Q1 2026, closing a stake of 69,415 shares — an estimated $535K sold.

Citadel Advisors first reported a position in DERM in Q4 2021 and held it in 6 quarters. The position peaked at $535K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Citadel Advisors reported no remaining Journey Medical position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 69,415 Journey Medical shares in Q1 2026, an estimated $535K.
  • Citadel Advisors first reported a position in Journey Medical in Q4 2021 and held it in 6 quarters.
  • Citadel Advisors's Journey Medical position peaked at $535K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.